A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment

Phase 2

Completed

• Conditions: Major Depressive Disorder
• Interventions: Drug: CERC-301; Other: Placebo

• Registration Number: NCT01941043
• Lead Sponsor: Avalo Therapeutics, Inc.

Brief Summary

The current study will evaluate the antidepressant effect of CERC-301 during 28 days of treatment in subjects with MDD who are currently experiencing a severe depressive episode despite stable ongoing treatment with selective serotonin- or serotonin-norepinephrine reuptake inhibitors (SSRI or SNRI). The study population will be enriched for subjects that would benefit most from rapid onset, those with recent active suicidal ideation, but not a risk to themselves or others and are deemed appropriate for an out-patient study with careful safety surveillance. This will allow the study to focus on the antidepressant effects of CERC-301 but also explore effects on suicidal ideation. To explore rapid onset, the primary endpoint will be at 7 days, but effects over the 28 days of treatment will be examined as a secondary endpoint.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-09-05
• Study First Submitted QC: 2013-09-09
• Study First Posted: 2013-09-13
• Study Start: 2013-11
• Primary Completion: 2014-09
• Study Completion: 2014-10
• Disposition First Submitted: 2017-09-18
• Disposition First Submitted QC: 2017-09-25
• Disposition First Posted: 2017-09-28
• Status Verified: 2017-12
• Last Update Submitted: 2017-12-19
• Last Update Posted: 2017-12-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1357

Inclusion Criteria

1. Male or female 18 to 70 years of age inclusive.

2. Females must be either:

   1. Post-menopausal (amenorrhea for at least 12 consecutive months), surgically sterile -or-
   2. Women of childbearing potential (WOCBP) meeting the criteria below:

   i. Uses an acceptable double-barrier method of contraception as determined by the Investigator -and- ii. Is not lactating, has a negative serum beta human chorionic gonadotropin pregnancy test at screening and a negative urine pregnancy test prior to randomization on Day 0.

3. Male subjects must agree to use a condom if partner is of childbearing potential.

4. Diagnosis of MDD recurrent without psychotic features according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria with diagnosis confirmed using the Structured Clinical Interview for DSM-IV Axis I Disorders Clinical Trials Version (SCID-CT).

5. Currently adhering to antidepressant drug regimen that consists of stable SSRI or SNRI therapy

6. Inadequate antidepressant response to current antidepressant therapy despite adequate dose and duration

7. HDRS-17 score ≥ 21 on the HDRS-17 performed by the site at screening

8. Recent active suicidal ideation defined as a score of 2 on the intensity of ideation section on the Columbia-Suicide Severity Rating Scale (C-SSRS) during the four weeks prior to screening using the "Baseline/Screening" version of the C-SSRS.

9. In otherwise good general health without any unstable medical conditions (as determined by medical history, physical examination, 12-lead ECG, clinical laboratory testing, etc.).

Exclusion Criteria

1. History of substance abuse or dependence within the 3 months prior to screening.

2. Positive urine drug test at screening and prior to randomization on Day 0 unless due to a permitted medication that is documented in the subject's medication history.

3. Positive ethanol breath test at screening and/or prior to randomization on Day 0.

4. Elevated semi-recumbent blood pressure at screening and prior to randomization on Day 0, defined as systolic blood pressure > 140 mm Hg and diastolic blood pressure

5. Active, comorbid disease that might limit the ability of the subject to participate in the study as determined by the Investigator (i.e. poorly controlled diabetes mellitus, unstable angina, coronary artery disease, congestive heart failure, etc.).

6. Subjects with clinical laboratory test abnormality deemed clinically significant by the Investigator at screening.

7. Axis I diagnosis of obsessive compulsive disorder, posttraumatic stress disorder, bipolar I or II mood disorders, eating disorders (e.g., anorexia nervosa, bulimia nervosa), psychotic disorders (e.g., schizoaffective disorder, schizophrenia), significant cognitive disorders (e.g., delirium, dementia, amnesia), or dissociative disorders.

8. Subjects with Axis II diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder.

9. Subjects with a neurologic disorder that could cause or contribute to depression (e.g., Alzheimer's disease, Parkinson's disease).

10. Female subjects currently experiencing postpartum depression.

11. Subjects who, in the opinion of the Investigator, are not appropriate for a 35-day placebo-controlled study due to risk of significant threat to self or others during screening or study conduct.

12. Use of other NMDA-receptor modulators (e.g., dextromethorphan, ketamine, amantadine, memantine) within 30 days of screening and throughout the study.

13. The following concomitant medication use is excluded within six weeks prior to screening:

    • Bupropion or tricyclic antidepressants
    • Intermittent, symptomatic use of benzodiazepines (e.g. symptomatic treatment of anxiety or panic attacks)
    • Antipsychotics
    • Lithium
    • Any medications known to directly interact with central or peripheral serotonergic receptors, other than the permitted antidepressants.
    • Any medications known to directly interact with central noradrenergic receptors, other than the permitted antidepressants.

14. Electroconvulsive therapy, transcranial magnetic stimulation, or vagal nerve stimulation during the current depressive episode.

15. Participation in an investigational drug or device study within the 6 months prior to screening.

16. Subjects with suicidal behavior within 6 months prior to screening as measured by the C-SSRS "Baseline/Screening" version.

17. Subjects with a C-SSRS score > 2 on the intensity of ideation section at randomization (Visit 2a), using the "Since Last Visit" version of the C-SSRS.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
CERC-301, Treatment Sequence 2	Placebo	Treatment Sequence 2 - Placebo for 7 days and study drug for 28 days (8 mgs)
CERC-301, Treatment Sequence 1	Placebo	Treatment Sequence 1 - 7 days on placebo and 28 days on study drug (either 12mg or 8mg)
Placebo, Treatment Sequence 3	Placebo	Treatment Sequence 3 - Placebo for 35 Day treatment period
CERC-301, Treatment Sequence 1	CERC-301	Treatment Sequence 1 - 7 days on placebo and 28 days on study drug (either 12mg or 8mg)
CERC-301, Treatment Sequence 2	CERC-301	Treatment Sequence 2 - Placebo for 7 days and study drug for 28 days (8 mgs)

Primary Outcome Measures

Name	Time	Method
HDRS-17 after 7 days of dosing with study drug	Screening & Days 0, 4, 7, 11, 14, 21,28, & 35	The overall between-treatment difference will be computed as the weighted average of the differences (drug vs. placebo)

Secondary Outcome Measures

Name	Time	Method
HDRS-17 after 28 days of dosing with study drug	Screening, Days 0, 4, 7, 11, 14, 21, 28, 35	This will be analyzed using the mixed effects model for repeated measures . The between-group difference will be estimates by the least squares mean difference at Day 28 as a simple contrast from the model.
HDRS-17 Averaged between 7 and 28 days of treatment with study drug	Screening, Days 0, 4, 7, 11, 14, 21, 28, & 35	This will be analyzed using the mixed effects model for repeated measures. The between-group (drug vs. placebo) differences will be estimated by the least squares mean for the contrast in the main effect.

Trial Locations

Locations (23)

Behavioral Research Specialists; 🇺🇸 Glendale, California, United States

ProScience Research Group; 🇺🇸 Culver City, California, United States

Bioscience Research; 🇺🇸 Mount Kisco, New York, United States

Northwest Clinical Research Center; 🇺🇸 Bellevue, Washington, United States

The Medical Research Network; 🇺🇸 New York, New York, United States

Finger Lakes Clinical Research; 🇺🇸 Rochester, New York, United States

Suburban Research Associates; 🇺🇸 Media, Pennsylvania, United States

PCRC; 🇺🇸 O'Fallon, Missouri, United States

Artemis Institute for Clinical Research; 🇺🇸 San Diego, California, United States

University of Alabama at Birmingham; 🇺🇸 Birmingham, Alabama, United States

Arizona TMS Therapy Center; 🇺🇸 Phoenix, Arizona, United States

Northwest Behavioral Research Center; 🇺🇸 Marietta, Georgia, United States

Chicago Psychiatry Associates; 🇺🇸 Chicago, Illinois, United States

Neuro-Behavioral Clinical Research, Inc.; 🇺🇸 Canton, Ohio, United States

FutureSearch Trials of Dallas; 🇺🇸 Dallas, Texas, United States

Sheppard Pratt Health System; 🇺🇸 Baltimore, Maryland, United States

Collaborative NeuroScience Network, Inc.; 🇺🇸 Garden Grove, California, United States

Synergy Clinical Research Center; 🇺🇸 National City, California, United States

Pacific Clinical Trials, LLC; 🇺🇸 Oakland, California, United States

Southern CA Psychiatrists; 🇺🇸 Oceanside, California, United States

Clinical Neuroscience Solutions; 🇺🇸 Orlando, Florida, United States

Atlanta Center for Medical Research; 🇺🇸 Atlanta, Georgia, United States

Scientific Clinical Research, Inc.; 🇺🇸 North Miami, Florida, United States